INT59555

From wiki-pain
Revision as of 23:41, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1993
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 39
Total Number 39
Disease Relevance 8.65
Pain Relevance 4.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (RYR1) transmembrane transport (RYR1) cytoplasm (RYR1)
Anatomy Link Frequency
skeletal muscle 3
brain 3
pore 2
liver 1
muscle 1
RYR1 (Homo sapiens)
RYR1 - G4898R (1)
Pain Link Frequency Relevance Heat
local anesthetic 41 100.00 Very High Very High Very High
lidocaine 33 99.88 Very High Very High Very High
Calcium channel 11 99.70 Very High Very High Very High
Paracetamol 4 94.40 High High
addiction 73 88.12 High High
backache 2 84.48 Quite High
anesthesia 87 73.24 Quite High
Versed 3 68.08 Quite High
Potency 17 65.60 Quite High
Central nervous system 9 62.92 Quite High
Disease Link Frequency Relevance Heat
Sprains And Strains 10 99.96 Very High Very High Very High
Central Core Disease 133 99.48 Very High Very High Very High
Malignant Hyperthermia 535 99.42 Very High Very High Very High
Hypertrophy 10 98.38 Very High Very High Very High
Myocardial Infarction 24 98.04 Very High Very High Very High
Coronary Artery Disease 16 97.74 Very High Very High Very High
Aging 6 96.76 Very High Very High Very High
Body Weight 9 96.00 Very High Very High Very High
Infection 18 92.76 High High
Disease 84 92.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As lymphoblastoid cell lines do not express the dihydropyridine receptor, they could also effectively be used to functionally test RYR1 mutations as well as to eliminate RYR1 as a causative factor in MH individuals who do not show linkage to RYR1.
RYR1 Neg (not) Binding (linkage) of associated with malignant hyperthermia
1) Confidence 0.42 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1867813 Disease Relevance 0.25 Pain Relevance 0.03
Forced relocation and public insurance were also associated with MHS-use in a later period.
MHS Binding (associated) of
2) Confidence 0.37 Published 2007 Journal BMC Public Health Section Body Doc Link PMC1949813 Disease Relevance 0.07 Pain Relevance 0
As lymphoblastoid cell lines do not express the dihydropyridine receptor, they could also effectively be used to functionally test RYR1 mutations as well as to eliminate RYR1 as a causative factor in MH individuals who do not show linkage to RYR1.
RYR1 Binding (eliminate) of associated with malignant hyperthermia
3) Confidence 0.37 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1867813 Disease Relevance 0.25 Pain Relevance 0.03
Nevertheless, these systems have proved useful in demonstrating abnormal calcium release associated with RYR1 mutations and it could be equally argued that these systems are representative of the genetic background of individual patients and therefore provide valuable information ex vivo.
RYR1 Binding (associated) of
4) Confidence 0.37 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1867813 Disease Relevance 0.21 Pain Relevance 0
The results of the second regression model showed that a high score on the SCL-90-R subscales, RAND-36 social functioning subscale and IES were all significantly associated with MHS use in the subsequent period (see table 5).
MHS Binding (associated) of
5) Confidence 0.36 Published 2007 Journal BMC Public Health Section Body Doc Link PMC1949813 Disease Relevance 0.08 Pain Relevance 0
We suggest that the newly identified RYR1 mutation is closely associated with MH and CCD.
RYR1 Binding (associated) of in RYR1 associated with central core disease
6) Confidence 0.36 Published 2004 Journal Am. J. Med. Genet. A Section Abstract Doc Link 14708096 Disease Relevance 1.07 Pain Relevance 0.06
Susceptibility to MH results from mutations in calcium channel proteins that mediate excitation-contraction coupling, with the ryanodine receptor calcium release channel (RyR1) representing the major locus.
ryanodine receptor Binding (mediate) of associated with calcium channel and malignant hyperthermia
7) Confidence 0.35 Published 2004 Journal Am J Forensic Med Pathol Section Abstract Doc Link 15577523 Disease Relevance 0.81 Pain Relevance 0.13
Susceptibility to MH results from mutations in calcium channel proteins that mediate excitation-contraction coupling, with the ryanodine receptor calcium release channel (RyR1) representing the major locus.
RyR1 Binding (mediate) of associated with calcium channel and malignant hyperthermia
8) Confidence 0.35 Published 2004 Journal Am J Forensic Med Pathol Section Abstract Doc Link 15577523 Disease Relevance 0.82 Pain Relevance 0.13
Another strength of our study is that we studied a MHS-unit which was specially implemented for disaster-related treatment and all patients registered in this unit suffered disaster-related problems.
MHS-unit Binding (implemented) of
9) Confidence 0.33 Published 2007 Journal BMC Public Health Section Body Doc Link PMC1949813 Disease Relevance 0.15 Pain Relevance 0
Younger age, forced relocation, immigrant status, public insurance, unemployment, and being injured as a result of the disaster were significantly associated with MHS-utilization within 18 months post-disaster (table 4).
MHS Binding (associated) of
10) Confidence 0.33 Published 2007 Journal BMC Public Health Section Body Doc Link PMC1949813 Disease Relevance 0.06 Pain Relevance 0
Among the strains, MHS was found to be unique for the smallest kidney size and New Zealand strains for the greatest relative LV size when adjusted to allow for the influence of BP.
MHS Binding (unique) of in kidney associated with sprains and strains
11) Confidence 0.32 Published 1993 Journal Heart Vessels Section Abstract Doc Link 8454565 Disease Relevance 1.31 Pain Relevance 0.06
To model the interactions of RyR1 pore with ions, we perform molecular dynamics simulations of the RyR1 pore tetramer with 70 mM CaCl2 and 250 mM KCl.
RyR1 Binding (interactions) of in pore
12) Confidence 0.30 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2668181 Disease Relevance 0.06 Pain Relevance 0
To model the interactions of RyR1 pore with ions and elucidate sites of high ion occupancy along the pore, we perform molecular dynamics simulations of RyR1 (see below).


RyR1 Binding (interactions) of in pore
13) Confidence 0.30 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2668181 Disease Relevance 0.06 Pain Relevance 0
In skeletal muscle, the rise in cytoplasmic Ca2+ is brought about by the opening of the ryanodine receptor (RyR1), which releases Ca2+ from intracellular stores [1],[2].
RyR1 Binding (opening) of in skeletal muscle
14) Confidence 0.24 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2668181 Disease Relevance 0.38 Pain Relevance 0
In skeletal muscle, the rise in cytoplasmic Ca2+ is brought about by the opening of the ryanodine receptor (RyR1), which releases Ca2+ from intracellular stores [1],[2].
ryanodine receptor Binding (opening) of in skeletal muscle
15) Confidence 0.24 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2668181 Disease Relevance 0.38 Pain Relevance 0
RyR1-G4898R is not responsive to Ca2+ and caffeine and does not bind ryanodine unlike RyR1-WT which points to major altered protein conformation of the mutant channel [28].
RyR1-G4898R (G4898R) Binding (bind) of
16) Confidence 0.23 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2668181 Disease Relevance 0 Pain Relevance 0.03
The interaction of local anesthetics with the ryanodine receptor of the sarcoplasmic reticulum.
ryanodine receptor Binding (interaction) of in reticulum associated with local anesthetic
17) Confidence 0.14 Published 1993 Journal J. Membr. Biol. Section Title Doc Link 8390576 Disease Relevance 0 Pain Relevance 0.65
Tetracaine interacts with the ryanodine receptor in a non-competitive fashion with respect to ryanodine but it competes with lidocaine for its binding site, suggesting the existence of a single site for the inhibitory and stimulatory LA.
ryanodine receptor Binding (interacts) of associated with lidocaine
18) Confidence 0.14 Published 1993 Journal J. Membr. Biol. Section Abstract Doc Link 8390576 Disease Relevance 0 Pain Relevance 0.64
Based on a structure-activity relationship, a model for the LA site of interaction in the ryanodine receptor is suggested.
ryanodine receptor Binding (interaction) of
19) Confidence 0.11 Published 1993 Journal J. Membr. Biol. Section Abstract Doc Link 8390576 Disease Relevance 0 Pain Relevance 0.44
Tetracaine and dibucaine inhibit binding of the photoreactive ATP analogue; [alpha-32P]benzoyl-benzoyl ATP (BzATP) to the ATP regulatory site of the ryanodine receptor, and high concentrations of ATP decrease the degree of ryanodine binding inhibition by tetracaine, indicating the relationship between the receptor conformations stabilized by ATP and LAs.
ryanodine receptor Binding (binding) of associated with local anesthetic
20) Confidence 0.11 Published 1993 Journal J. Membr. Biol. Section Abstract Doc Link 8390576 Disease Relevance 0 Pain Relevance 0.66

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox